Evidence map›Paper›PMID 34787781›Full record

ArticleBulletin of experimental biology and medicine2021

Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.

A A Chepurnov, E I Kazachinskaya, E A Kazachkova, K A Sharshov, Yu V Kononova, A A Shelemba, A Yu Alekseev, M A Gulyeva, M I Voevoda, A M Shestopalov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A A ChepurnovFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia. alexa.che.purnov@gmail.com.
E I KazachinskayaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
E A KazachkovaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
K A SharshovFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
Yu V KononovaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
A A ShelembaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
A Yu AlekseevFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
M A GulyevaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
M I VoevodaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
A M ShestopalovFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Different methods for producing bulk quantities of concentrated and purified SARS-CoV-2 for the use as antigens and for the research into COVID-19 biology were tested.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCell LineChlorocebus aethiopsConvalescenceCOVID-19COVID-19 TestingEpithelial CellsHumansImmune SeraSARS-CoV-2SwineVero CellsViral LoadViral ProteinsAntibodies, NeutralizingAntibodies, ViralImmune SeraViral Proteins2002 year SARS-CoVelectrophoresispurified virus preparationsSARS-CoV-2

Identifiers

PMID34787781
PMCPMC8596366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.